Particularités histologiques d’un cas de syndrome de Sweet déclenché par le G-CSF

Abecassis, S.; Ingen‐Housz‐Oro, Saskia; Cavelier‐Balloy, B.; Arnulf, Bertrand; Bachelez, Hervé; Dubertret, Louis

doi:10.1016/s0151-9638(04)93617-4

Cited by 14 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 In patients with cancer who receive chemotherapies and growth factors, a wide variety of skin reactions may be observed including local reactions on the injection site, leukocytoclastic vasculitis, growth of vascular tumors, and especially neutrophilic dermatoses. [5][6][7][8][9][10][11][12] Reports on cutaneous drug eruptions after application of erythropoietin are very rare. Hardwick and King 13 observed a patient with generalized eczema after treatment with erythropoietin.…”

Section: Discussionmentioning

confidence: 99%

Erythroderma with lichenoid granulomatous features induced by erythropoietin

et al. 2005

View full text Add to dashboard Cite

The increasing use of new drugs in cancer therapy, especially growth factors, hormones, and chemotherapies resulted in several reports of unusual skin eruptions. We studied a patient with erythroderma who had received erythropoietin because of myeloma with tumor anemia. The histological features were characterized by a lichenoid, focally granulomatous infiltrate with predominance of histiocytes. It is important for dermatopathologists to recognize this interesting pattern induced by erythropoietin.

show abstract

Section: Discussionmentioning

confidence: 99%

Erythroderma with lichenoid granulomatous features induced by erythropoietin

et al. 2005

View full text Add to dashboard Cite

show abstract

“…From a dermatological standpoint, G-CSF therapy has been linked to various manifestations, such as pyoderma gangrenosum [58], Sweet's syndrome [59][60][61][62][63][64][65], other neutrophilic dermatoses [66], granulomatous dermatitis [67], widespread folliculitis [68], cutaneous vasculitis [50,[69][70][71][72], and exacerbations of acne [73] and psoriasis [70,74,75]. Several cases of cutaneous eruptions containing leukemic cells have been reported (without their presence in the bone marrow or blood) after G-CSF, suggesting the skin's ability to simulate malignancies, as well as its dependency on G-CSF administration [76,77].…”

Section: Adverse Reactions To G-csfmentioning

confidence: 99%

Balancing Benefits and Risks: A Literature Review on Hypersensitivity Reactions to Human G-CSF (Granulocyte Colony-Stimulating Factor)

Bumbăcea,

Udrea,

Ali

et al. 2024

IJMS

View full text Add to dashboard Cite

Human granulocyte colony-stimulating factor (G-CSF) is a granulopoietic growth factor used in the treatment of neutropenia following chemotherapy, myeloablative treatment, or healthy donors preparing for allogeneic transplantation. Few hypersensitivity reactions (HRs) have been reported, and its true prevalence is unknown. We aimed to systematically characterize G-CSF-induced HRs while including a comprehensive list of adverse reactions. We reviewed articles published before January 2024 by searching in the PubMed, Embase, Cochrane Library, and Web of Science databases using a combination of the keywords listed, selected the ones needed, and extracted relevant data. The search resulted in 68 entries, 17 relevant to our study and 7 others found from manually searching bibliographic sources. A total of 40 cases of G-CSF-induced HR were described and classified as immediate (29) or delayed (11). Immediate ones were mostly caused by filgrastim (13 minimum), with at least 9 being grade 5 on the WAO anaphylaxis scale. Delayed reactions were mostly maculopapular exanthemas and allowed for the continuation of G-CSF. Reactions after first exposure frequently appeared and were present in at least 11 of the 40 cases. Only five desensitization protocols have been found concerning the topic at hand in the analyzed data. We believe this study brings to light the research interest in this topic that could benefit from further exploration, and propose regular updating to include the most recently published evidence.

show abstract

“…Several cutaneous eruptions have been reported in relation to these treatments. Locally induced eruptions, at injections sites, such as nodule or erythematous edematous plaque and neutrophilic dermatosis, like Sweet's syndrome, bullous pyoderma gangrenosum, cutaneous vasculitis have been reported [36][37][38][39][40][41][42]. Robak et al reported a case of toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF [43].…”

Section: Granulocyte and Granulocyte-macrophage Colonystimulating Facmentioning

confidence: 99%

Cytokines Induced Skin Adverse Reactions

Meng¹

2014

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

Particularités histologiques d’un cas de syndrome de Sweet déclenché par le G-CSF

Cited by 14 publications

References 17 publications

Erythroderma with lichenoid granulomatous features induced by erythropoietin

Erythroderma with lichenoid granulomatous features induced by erythropoietin

Balancing Benefits and Risks: A Literature Review on Hypersensitivity Reactions to Human G-CSF (Granulocyte Colony-Stimulating Factor)

Cytokines Induced Skin Adverse Reactions

Contact Info

Product

Resources

About